Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B

Background and Aim:  Acute exacerbation of chronic hepatitis B has to be distinguished from acute hepatitis, because treatment strategies differ between them.

[1]  Yasuhiro Tanaka,et al.  Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  C. Galli,et al.  Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  Yoshiyuki Suzuki,et al.  Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C , 2006, Journal of medical virology.

[4]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  M. Sata,et al.  A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  Yoshiyuki Suzuki,et al.  Clinical and virological features of non‐breakthrough and severe exacerbation due to lamivudine‐resistant hepatitis B virus mutants , 2006, Journal of medical virology.

[7]  Yoshiyuki Suzuki,et al.  Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B , 2004, Journal of gastroenterology and hepatology.

[8]  Yoshiyuki Suzuki,et al.  Adefovir Dipivoxil for Treatment of Breakthrough Hepatitis Caused by Lamivudine-Resistant Mutants of Hepatitis B Virus , 2004, Intervirology.

[9]  N. Izumi,et al.  Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. , 2003, Journal of hepatology.

[10]  M. Mizokami,et al.  Classifying Hepatitis B Virus Genotypes , 2003, Intervirology.

[11]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[12]  S. Hadziyannis,et al.  Diagnosis and management of pre‐core mutant chronic hepatitis B , 2001, Journal of viral hepatitis.

[13]  William M. Lee,et al.  Hepatitis B infection in patients with acute liver failure in the United States , 2001, Hepatology.

[14]  C. Hunt,et al.  Clinical relevance of hepatitis B viral mutations , 2000, Hepatology.

[15]  Y. Kato,et al.  Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan , 1998, Journal of gastroenterology and hepatology.

[16]  H. Okamoto,et al.  Hepatitis B Virus Strains with Mutations in the Core Promoter in Patients with Fulminant Hepatitis , 1995, Annals of Internal Medicine.

[17]  F Tsuda,et al.  Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen , 1994, Journal of virology.

[18]  J. Wands,et al.  A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. , 1991, The New England journal of medicine.

[19]  O. Yokosuka,et al.  Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. , 1991, The New England journal of medicine.

[20]  F Tsuda,et al.  Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen , 1990, Journal of virology.

[21]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[22]  F. Tsuda,et al.  Low molecular weight (7s) immunoglobulin M antibody against hepatitis B core antigen in the serum for differentiating acute from persistent hepatitis B virus infection , 1984 .

[23]  F. Tsuda,et al.  Immunoglobulin M Antibody Against Hepatitis B Core Antigen for the Diagnosis of Fulminant Type B Hepatitis , 1983 .

[24]  J. Summers,et al.  Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate , 1982, Cell.

[25]  B. Koblin,et al.  Hepatitis B virus infection. , 1998, The New England journal of medicine.

[26]  A. Seppäläinen,et al.  Encephalopathy and neuropathy in end-stage liver disease before and after liver transplantation. , 1992, Journal of hepatology.